ABSTRACT
Background Lung cancer remains the leading cause of cancer-related mortality in the United States, with screening adherence rates below 16% nationally and even lower among underserved populations [1–4]. Federally Qualified Health Centers (FQHCs), which serve over 30 million patients annually, face significant challenges in identifying screening-eligible individuals due to workforce constraints, manual workflows, and limited clinical decision support (CDS) infrastructure [5–7].
Objective We developed and evaluated an AI-driven, natural language (NLP)-enhanced CDS platform designed to automate lung cancer screening eligibility determination and integrate seamlessly into the workflows of FQHCs.
Methods The platform combines a deterministic rules engine, encoding the U.S. Preventive Services Task Force (USPSTF) 2021 screening criteria, with an NLP pipeline built using SciSpacy and MedSpaCy to extract smoking history details from unstructured clinical notes. Structured and unstructured data were unified using FHIR-compliant APIs to generate actionable screening flags within simulated FQHC workflows.
Results In a synthetic cohort modeled on FQHC populations, the platform achieved precision, recall, and F1-scores above 0.90 for eligibility determination and reduced manual chart review workload by 62%. It generated clear, auditable recommendations aligned with Centers for Medicare & Medicaid Services (CMS) coverage policies and Healthcare Effectiveness Data and Information Set (HEDIS) quality measures, while identifying additional high-risk patients who may have been missed in manual reviews.
Conclusion This work demonstrates the feasibility of an AI-powered CDS framework for improving lung cancer screening adherence in resource-limited primary care settings. Future development will focus on prospective validation, expansion to other preventive screenings and population health use cases, and integration of explainable AI to enhance clinical trust and scalability.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://github.com/adey1998/onqi-research
Funding Statement
This research was conducted without external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used only synthetic and fully de-identified patient data; therefore, institutional review board (IRB) approval was not required under federal guidelines for human subjects research. All development and evaluation procedures adhered to the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule, ensuring that patient confidentiality was maintained throughout the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in this study are synthetic and generated for research purposes. The data and scripts used to generate them are available upon reasonable request to the corresponding author.
